IGC Pharma, Inc. announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (PK) of delta-9-tetrahydrocannabinol (THC) and its active metabolite in Alzheimer?s disease (AD) patients. The publication is titled A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ?-9-tetrahydrocannabinol.

The article highlights the importance of understanding genetic variations in CYP2C9, an enzyme crucial for drug metabolism, and its impact on the efficacy and safety of treatments involving THC. IGC Pharma?s leading drug candidate IGC-AD1 was tested in a Phase 1 multiple ascending dose (?MAD?) trial with a Puerto Rican population. The study examined the effect of CYP2C9 polymorphisms on THC metabolism in AD patients.

Key findings revealed significant variations in THC and OH-THC half-life among different CYP2C9 phenotypes, suggesting the need for personalized dosing strategies in AD patients. The publication of the article aligns with IGC Pharma?s commitment to the inclusion of underrepresented populations in clinical research developing innovative Alzheimer's therapies. Puerto Rico, with an elevated AD rate of 12% compared to 10.7% in the continental US, was chosen to ensure comprehensive data collection and improve the accessibility of effective therapies.

IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties and an inflammasome inhibitor, to treat agitation from symptoms of dementia caused by Alzheimer?s. Neuroinflammation, neurotransmitter imbalance, loss of CB1r, and inflammasome-3 have been implicated as causes of agitation and aggression in patients suffering from Alzheimer?s disease. IGC-AD1 contains THC as one of its two active pharmaceutical agents, the principal psychoactive cannabinoid found in Cannabis. IGC-AD1 is a first-of-its-kind THC-based-formulation undergoing a formal Phase 2 clinical trial in Alzheimer?s disease.